ライフサイエンスコーパス: fibrofatty

1 ied (1.3 [0.49 mm(2)] vs. 1.0 [0.40 mm(2)]), fibrofatty (0.23 [0.15 mm(2)] vs. 0.11 [0.087 mm(2)]), a

2 [32.2] mm3 vs 5.6 [28.5] mm3; P = .002), and fibrofatty and necrotic core plaque volume (mean [SD], 4

3 pical region, but was less extensive than in fibrofatty ARVC and FaRV.

4 Fibrofatty ARVC was characterized by right ventricular m

5 Patients with fibrofatty ARVC were younger than those with FaRV (31+/-

6 6 sections each from 25 hearts with typical (fibrofatty) ARVC, 7 hearts with fat replacement of the r

7 ted with noncalcified (B = 0.28; P < 0.001), fibrofatty (B = 0.49; P < 0.001), and lipid-rich necroti

8 with noncalcified (beta = 0.28; P < 0.001), fibrofatty (beta = 0.49; P < 0.001), and lipid-rich necr

9 characterize plaque broadly as calcified or fibrofatty but was limited in its ability to more precis

10 cintigraphy, and finally, attenuation of the fibrofatty changes of the skin, the final consequences o

11 ed myocyte apoptosis in skeletal muscle; and fibrofatty connective tissue proliferation around joints

12 population, the mean percentage of fibrous, fibrofatty, dense calcified, and necrotic core plaques i

13 ARVC is characterized pathologically by fibrofatty infiltration and clinically by arrhythmias an

14 m RyR2(R176Q/+) mice revealed no evidence of fibrofatty infiltration or structural abnormalities char

15 MRI of the leg muscles showed fibrofatty infiltration predominating in the posterior t

16 Among whole hearts, the most common areas of fibrofatty infiltration were the left ventricular poster

17 als additional pathogenic potential, causing fibrofatty infiltration within the myocardium and drivin

18 In scar, myocytes adjacent to fibrofatty interfaces demonstrated increased connexin43

19 Atherosclerosis, the formation of fibrofatty lesions in the artery wall, causes much morbi

20 se distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the ar

21 ydroxylase positive, were present within the fibrofatty matrix and within the myocardial tracts.

22 acking is associated with the severity of LA fibrofatty myocardial remodeling at histologic analysis.

23 ion was found between PLAS and the degree of fibrofatty myocardial replacement at histologic analysis

24 001) and regression of fibrous (P<0.001) and fibrofatty (P<0.001) tissue.

25 plaque (median 76.1 vs 31.1, P = .003), and fibrofatty plaque (median 63.6 vs 27.6, P < .001) volume

26 ), mesenteric signs such as hyperemia (n=9), fibrofatty proliferation (n=8) and lymphadenopathy (n=28

27 Fibrofatty proliferation of mesenteric fat is a common f

28 ll thickening, stricture, abscess formation, fibrofatty proliferation, and fat edema.

29 t correlate with the histologic degree of LA fibrofatty replacement (r = -0.35, P = .330).

30 muscle disorder characterized by myocardial fibrofatty replacement and an increased risk of sudden c

31 myopathy, characterized by right ventricular fibrofatty replacement and arrhythmias, causes sudden de

32 cal cardiac phenotypes, including myocardial fibrofatty replacement and sudden cardiac death.

33 PLAS, correlates strongly with the degree of fibrofatty replacement at histologic analysis.

34 reas the heart showed extensive fibrosis and fibrofatty replacement in both ventricles.

35 hen junctions are disrupted, cell death, and fibrofatty replacement occur.

36 athy (ARVD/C) is a disorder characterized by fibrofatty replacement of cardiac myocytes that typicall

37 ning arrhythmias, myocardial dysfunction and fibrofatty replacement of myocardial tissue.

38 eritable myocardial disorder associated with fibrofatty replacement of myocardium and ventricular arr

39 lial arrhythmogenic disease characterized by fibrofatty replacement of myocytes with scattered foci o

40 ar cardiomyopathy (ARVC) is characterized by fibrofatty replacement of primarily the right ventricula

41 ogical features include loss of myocytes and fibrofatty replacement of right ventricular myocardium;

42 An ARVD/C is characterized by fibrofatty replacement of RV myocardium and RV dilation.

43 genetic myocardial disease characterized by fibrofatty replacement of the myocardium and a predispos

44 is a rare inherited disease characterized by fibrofatty replacement of the myocardium, associated wit

45 n inherited cardiac disease characterized by fibrofatty replacement of the myocardium, resulting in h

46 ized by dilation of the cardiac chambers and fibrofatty replacement of the myocardium, which results

47 rdiomyopathy characterized pathologically by fibrofatty replacement primarily of the RV and clinicall

48 lleviated the phenotypic ACM features (i.e., fibrofatty replacement, contractile dysfunction, and ven

49 L leads to sustained cardiomyocyte death and fibrofatty replacement.

50 characteristic of ARVC is myocyte loss with fibrofatty replacement.

51 TMEM43 causes cardiomyocyte death and severe fibrofatty replacement.

52 ht ventricle, subepicardial left ventricular fibrofatty replacements (64%), myocyte atrophy (96%), an

53 atal growth followed by slow regression to a fibrofatty residuum.

54 c right ventricular cardiomyopathy (ARVC) is fibrofatty scar replacement.

55 nvolution were telangiectasias (145, 84.3%), fibrofatty tissue (81, 47.1%), and anetodermic skin (56,

56 osition in CAV may include early fibrous and fibrofatty tissue and late atheromatous calcification.

57 ncluding fibre size variability, presence of fibrofatty tissue of varying severity, without specific

58 r disorder characterized by myocyte loss and fibrofatty tissue replacement of the right ventricle.

59 d by progressive loss of cardiomyocytes with fibrofatty tissue replacement, systolic dysfunction, and

60 d by progressive loss of cardiomyocytes, and fibrofatty tissue replacement.

61 lcium progression, regression of fibrous and fibrofatty tissue, and excessive expansive remodeling, s

62 n which the right ventricle is "replaced" by fibrofatty tissue, resulting in lethal arrhythmias.

63 rdial tracts (Marshall Bundles) insulated by fibrofatty tissue.

64 eletal muscle mass (MM) and replacement with fibrofatty tissue.